Loading...

Terumo

DB:TUO
Snowflake Description

Flawless balance sheet second-rate dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TUO
DB
¥2,341B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
TUO Share Price and Events
7 Day Returns
-4.3%
DB:TUO
-2.3%
DE Medical Equipment
-1.1%
DE Market
1 Year Returns
8.1%
DB:TUO
6%
DE Medical Equipment
-8.5%
DE Market
TUO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Terumo (TUO) -4.3% -0.9% 3.1% 8.1% 31.5% 208.1%
DE Medical Equipment -2.3% -1.7% 3.4% 6% 108.2% 255.7%
DE Market -1.1% -0.4% -4% -8.5% 8.1% 9.4%
1 Year Return vs Industry and Market
  • TUO outperformed the Medical Equipment industry which returned 6% over the past year.
  • TUO outperformed the Market in Germany which returned -8.5% over the past year.
Price Volatility
TUO
Industry
5yr Volatility vs Market

TUO Value

 Is Terumo undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Terumo to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Terumo.

DB:TUO Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 11 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:TUO
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.871 (1 + (1- 30.86%) (9.62%))
0.952
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.952 * 5.96%)
5.9%

Discounted Cash Flow Calculation for DB:TUO using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Terumo is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:TUO DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 5.9%)
2020 43,605.25 Analyst x4 41,174.67
2021 80,896.40 Analyst x5 72,129.34
2022 92,518.40 Analyst x5 77,893.69
2023 95,600.00 Analyst x2 76,001.72
2024 109,600.00 Analyst x2 82,274.92
2025 116,903.86 Est @ 6.66% 82,866.15
2026 122,437.24 Est @ 4.73% 81,950.81
2027 126,577.69 Est @ 3.38% 79,999.68
2028 129,660.59 Est @ 2.44% 77,380.31
2029 131,959.87 Est @ 1.77% 74,362.81
Present value of next 10 years cash flows ¥746,034.12
DB:TUO DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ¥131,959.87 × (1 + 0.23%) ÷ (5.9% – 0.23%)
¥2,330,550.82
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥2,330,550.82 ÷ (1 + 5.9%)10
¥1,313,325.74
DB:TUO Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥746,034.12 + ¥1,313,325.74
¥2,059,359.86
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥2,059,359.86 / 743.12
¥2771.22
DB:TUO Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:TUO represents 0.00814x of TSE:4543
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.00814x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 2,771.22 x 0.00814
€22.56
Value per share (EUR) From above. €22.56
Current discount Discount to share price of €25.64
= -1 x (€25.64 - €22.56) / €22.56
-13.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Terumo is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Terumo's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Terumo's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:TUO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in JPY ¥108.70
TSE:4543 Share Price ** TSE (2019-07-19) in JPY ¥3150
Germany Medical Equipment Industry PE Ratio Median Figure of 10 Publicly-Listed Medical Equipment Companies 31.63x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Terumo.

DB:TUO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4543 Share Price ÷ EPS (both in JPY)

= 3150 ÷ 108.70

28.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Terumo is good value based on earnings compared to the DE Medical Equipment industry average.
  • Terumo is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Terumo's expected growth come at a high price?
Raw Data
DB:TUO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 28.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
8.3%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 2.49x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

DB:TUO PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 28.98x ÷ 8.3%

3.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Terumo is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Terumo's assets?
Raw Data
DB:TUO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in JPY ¥939.60
TSE:4543 Share Price * TSE (2019-07-19) in JPY ¥3150
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.07x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.73x
DB:TUO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4543 Share Price ÷ Book Value per Share (both in JPY)

= 3150 ÷ 939.60

3.35x

* Primary Listing of Terumo.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Terumo is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Terumo's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Terumo has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

TUO Future Performance

 How is Terumo expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
8.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Terumo expected to grow at an attractive rate?
  • Terumo's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Terumo's earnings growth is positive but not above the Germany market average.
  • Terumo's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:TUO Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:TUO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 8.3%
DB:TUO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 5.5%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:TUO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:TUO Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 794,285 160,917 119,458 4
2023-03-31 754,885 151,647 110,230 4
2022-03-31 711,640 142,076 104,352 9
2021-03-31 675,421 131,684 94,122 11
2020-03-31 638,644 122,309 84,733 11
DB:TUO Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2019-03-31 599,481 93,571 79,470
2018-12-31 594,429 84,305
2018-09-30 588,162 106,706 92,782
2018-06-30 591,483 93,095
2018-03-31 587,775 114,562 91,295
2017-12-31 576,725 85,888
2017-09-30 553,664 87,995 66,769
2017-06-30 528,957 60,406
2017-03-31 514,164 80,862 54,225
2016-12-31 503,429 39,014
2016-09-30 510,969 85,463 44,087
2016-06-30 520,885 46,282

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Terumo's earnings are expected to grow by 8.3% yearly, however this is not considered high growth (20% yearly).
  • Terumo's revenue is expected to grow by 5.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:TUO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Terumo Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TUO Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31 161.50 171.00 146.00 4.00
2023-03-31 149.00 153.20 139.20 4.00
2022-03-31 139.17 157.91 125.37 10.00
2021-03-31 125.39 136.27 111.87 12.00
2020-03-31 113.79 124.19 105.67 12.00
DB:TUO Past Financials Data
Date (Data in JPY Millions) EPS *
2019-03-31 108.70
2018-12-31 116.73
2018-09-30 130.15
2018-06-30 131.71
2018-03-31 129.56
2017-12-31 121.69
2017-09-30 93.87
2017-06-30 84.27
2017-03-31 75.07
2016-12-31 53.53
2016-09-30 59.97
2016-06-30 62.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Terumo is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Terumo's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Terumo has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

TUO Past Performance

  How has Terumo performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Terumo's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Terumo has delivered over 20% year on year earnings growth in the past 5 years.
  • Terumo's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Terumo's 1-year earnings growth is negative, it can't be compared to the DE Medical Equipment industry average.
Earnings and Revenue History
Terumo's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Terumo Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TUO Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 599,481.00 79,470.00 164,359.00 47,681.00
2018-12-31 594,429.00 84,305.00 153,024.00 41,342.00
2018-09-30 588,162.00 92,782.00 156,221.00 41,342.00
2018-06-30 591,483.00 93,095.00 157,227.00 41,342.00
2018-03-31 587,775.00 91,295.00 157,317.00 41,342.00
2017-12-31 576,725.00 85,888.00 193,625.00 33,747.00
2017-09-30 553,664.00 66,769.00 182,849.00 33,747.00
2017-06-30 528,957.00 60,406.00 174,204.00 33,747.00
2017-03-31 514,164.00 54,225.00 167,674.00 33,747.00
2016-12-31 503,429.00 39,014.00 165,897.00 33,147.00
2016-09-30 510,969.00 44,087.00 166,433.00 33,147.00
2016-06-30 520,885.00 46,282.00 168,822.00 33,147.00
2016-03-31 525,026.00 50,676.00 170,050.00 33,147.00
2015-12-31 522,296.00 48,528.00 171,933.00 29,360.00
2015-09-30 515,364.00 43,603.00 169,516.00 29,360.00
2015-06-30 503,221.00 44,580.00 164,216.00 29,360.00
2015-03-31 489,506.00 38,470.00 159,209.00 29,360.00
2014-12-31 485,301.00 30,626.00 131,277.00 30,130.00
2014-09-30 474,640.00 36,517.00 179,994.00
2014-06-30 471,214.00 33,534.00 177,652.00
2014-03-31 467,360.00 34,096.00 123,878.00 30,130.00
2013-12-31 451,805.00 59,203.00 134,589.00 27,128.00
2013-09-30 436,490.00 51,948.00 129,375.00 27,128.00
2013-06-30 417,517.00 47,811.00 122,489.00 27,128.00
2013-03-31 402,294.00 47,014.00 107,085.00 27,129.00
2012-12-31 393,521.00 26,912.00 114,146.00 24,322.00
2012-09-30 387,800.00 20,979.00 111,197.00 24,322.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Terumo has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Terumo used its assets more efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • Terumo's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Terumo's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Terumo has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

TUO Health

 How is Terumo's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Terumo's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Terumo is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Terumo's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Terumo's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Terumo Company Filings, last reported 3 months ago.

DB:TUO Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 698,112.00 225,134.00 122,982.00
2018-12-31 672,356.00 275,702.00 161,063.00
2018-09-30 678,080.00 278,376.00 180,746.00
2018-06-30 598,530.00 321,093.00 162,918.00
2018-03-31 550,435.00 336,211.00 167,832.00
2017-12-31 554,008.00 365,216.00 154,259.00
2017-09-30 527,964.00 365,323.00 146,261.00
2017-06-30 503,645.00 365,932.00 124,142.00
2017-03-31 489,552.00 345,625.00 105,388.00
2016-12-31 540,904.00 353,255.00 264,156.00
2016-09-30 478,116.00 249,357.00 155,383.00
2016-06-30 474,923.00 251,730.00 166,987.00
2016-03-31 511,544.00 224,408.00 149,672.00
2015-12-31 591,309.00 230,395.00 191,508.00
2015-09-30 577,331.00 230,801.00 190,752.00
2015-06-30 588,340.00 234,149.00 169,993.00
2015-03-31 573,521.00 233,822.00 179,679.00
2014-12-31 578,724.00 278,553.00 209,658.00
2014-09-30 536,183.00 176,791.00 103,988.00
2014-06-30 496,717.00 175,246.00 85,030.00
2014-03-31 496,245.00 161,682.00 95,619.00
2013-12-31 511,405.00 189,653.00 94,866.00
2013-09-30 469,931.00 186,126.00 84,631.00
2013-06-30 461,578.00 190,407.00 79,584.00
2013-03-31 437,909.00 180,520.00 78,201.00
2012-12-31 385,034.00 190,120.00 72,706.00
2012-09-30 345,995.00 180,623.00 62,958.00
  • Terumo's level of debt (32.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (32.7% vs 32.2% today).
  • Debt is well covered by operating cash flow (41.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 190.1x coverage).
X
Financial health checks
We assess Terumo's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Terumo has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

TUO Dividends

 What is Terumo's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.89%
Current annual income from Terumo dividends. Estimated to be 1.01% next year.
If you bought €2,000 of Terumo shares you are expected to receive €18 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Terumo's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.49%).
  • Terumo's dividend is below the markets top 25% of dividend payers in Germany (3.92%).
Upcoming dividend payment

Purchase Terumo before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:TUO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:TUO Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2024-03-31 38.33 3.00
2023-03-31 36.00 3.00
2022-03-31 33.00 9.00
2021-03-31 30.65 10.00
2020-03-31 28.45 10.00
DB:TUO Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-06-24 28.000 0.871
2019-05-09 28.000 0.894
2019-02-12 27.000 0.800
2018-11-12 27.000 0.865
2018-11-08 27.000 0.850
2018-06-25 27.000 0.862
2018-05-09 27.000 0.839
2018-02-13 23.000 0.810
2018-02-08 23.000 0.874
2017-11-13 23.000 0.870
2017-11-09 23.000 0.947
2017-06-28 22.000 0.995
2017-05-10 22.000 0.993
2017-02-13 21.000 1.061
2017-02-09 21.000 1.046
2016-11-14 21.000 1.011
2016-11-10 21.000 1.073
2016-06-27 20.500 0.980
2016-05-10 20.500 0.924
2016-02-12 19.000 0.941
2016-02-04 19.000 0.981
2015-11-12 19.000 1.001
2015-11-05 19.000 0.977
2015-05-08 16.000 1.020
2015-02-12 14.500 0.903
2015-02-03 14.500 0.941
2014-11-12 14.500 1.042
2014-11-05 14.500 1.036
2014-06-25 14.500 1.174
2014-05-08 14.500 1.359
2014-02-04 14.500 1.329
2013-11-13 14.500 1.144
2013-11-06 14.500 1.191
2013-08-01 14.500 1.201
2013-05-09 14.500 1.160
2013-02-12 11.000 1.044
2013-01-31 11.000 1.103
2012-11-13 11.000 1.260
2012-10-30 11.000 1.307
2012-07-31 11.000 1.296
2012-06-29 11.000 1.359
2012-05-10 11.000 1.473
2012-02-13 8.500 0.902
2012-01-30 8.500 0.947
2011-11-11 8.500 0.926
2011-07-28 8.500 0.857
2011-06-30 8.000 0.720
2011-05-11 8.000 0.728
2011-02-10 8.000 0.729
2011-01-27 8.000 0.735
2010-11-12 8.000 0.704
2010-10-28 8.000 0.750
2010-06-03 8.000 0.726
2010-02-12 8.000 0.666
2010-01-28 8.000 0.637
2009-11-12 8.000 0.615
2009-10-15 8.000 0.677
2009-05-13 8.000 0.732
2008-10-30 8.000 0.885
2008-07-30 8.000 0.621

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Terumo's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Terumo's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Terumo afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Terumo has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

TUO Management

 What is the CEO of Terumo's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shinjiro Sato
TENURE AS CEO 2.3 years
CEO Bio

Mr. Shinjiro Sato has been the President and Chief Executive Officer at Terumo Corporation since April 2017 and served as its Managing Executive Officer of Terumo Corporation since April 2015. Mr. Sato serves as President of Cardiac & Vascular Company at Terumo Corporation. Mr. Sato served as Director of Olympus Terumo Biomaterials Corp. He served as Senior Executive Officer of Terumo Corporation since June 2012 until April 2015. He served as General Manager of Strategy Planning Department at Terumo Corporation. Mr. Sato has been a Director of Terumo Corporation since June 2014. In April 1984, he joined Toa Nenryo Kogyo K.K. (currently JXTG Nippon Oil & Energy Corporation). In February 1999, he Joined Arthur Andersen Business Consulting (currently PwC Japan Group). In June 2004, he Joined Terumo Corporation and was its Executive Officer and General Manager of Strategic Planning Dept. since June 2010. He was Group President of Cardiac and Vascular Business Group since October 2011.

CEO Compensation
  • Insufficient data for Shinjiro to compare compensation growth.
  • Insufficient data for Shinjiro to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the Terumo management team in years:

3.3
Average Tenure
  • The tenure for the Terumo management team is about average.
Management Team

David Perez

TITLE
Senior Executive Officer & Director
COMPENSATION
¥298M
AGE
60
TENURE
5.1 yrs

Shinjiro Sato

TITLE
President
TENURE
2.3 yrs

Ryo Nishihata

TITLE
Senior Executive Officer and Chief Accounting & Financial Officer
TENURE
2.5 yrs

Hiroaki Kasukawa

TITLE
CTO & Executive Officer

Katsuya Takeuchi

TITLE
Chief Information Officer & Executive Officer
TENURE
3.3 yrs

Miho Mizuguchi

TITLE
Executive Officer
TENURE
3.3 yrs

Atsuo Omagari

TITLE
General Manager of Corporate Communication Department

Kyo Nishikawa

TITLE
Senior Executive Officer & Chief Human Resources Officer

Toshiaki Takagi

TITLE
Senior Managing Executive Officer
TENURE
4.3 yrs

Jim Rushworth

TITLE
Executive Officer
Board of Directors Tenure

Average tenure and age of the Terumo board of directors in years:

4.1
Average Tenure
64.5
Average Age
  • The tenure for the Terumo board of directors is about average.
Board of Directors

Takayoshi Mimura

TITLE
Chairman of the Board
TENURE
2.3 yrs

David Perez

TITLE
Senior Executive Officer & Director
COMPENSATION
¥298M
AGE
60
TENURE
5.1 yrs

Shinjiro Sato

TITLE
President
TENURE
5.1 yrs

Toshiaki Takagi

TITLE
Senior Managing Executive Officer
TENURE
9.1 yrs

Shoji Hatano

TITLE
Managing Executive Officer & Director
TENURE
3.1 yrs

Toshihiko Matsumiya

TITLE
Independent Director
TENURE
4.1 yrs

Masatake Yone

TITLE
Independent Director
AGE
65
TENURE
4.1 yrs

Yoshihiro Kimura

TITLE
Director
AGE
64
TENURE
2.1 yrs

Ikuo Mori

TITLE
Independent Director
AGE
72
TENURE
5.1 yrs

Ryuzo Ueda

TITLE
Independent Director
TENURE
4.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Terumo's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Terumo has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

TUO News

Simply Wall St News

TUO Company Info

Description

Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. It provides products for use in cardiothoracic surgery, interventional procedure, and medicine transfusion. The company offers vascular intervention devices, such as introducer sheathes, guide wires, angiographic catheters, and radial artery compression devices; therapeutic devices; and intravascular imaging systems, including optical frequency domain imaging and intravascular ultrasound systems. It also provides interventional oncology devices, such as micro balloon catheters, micro catheters and guide wires, and drug-elutable beads; cardiopulmonary bypass systems comprising oxygenators with integrated arterial filters, heart-lung machines, and devices for operating a centrifugal pumps for extracorporeal life support systems; and thoracic vascular and abdominal vascular grafts. In addition, the company offers infusion systems; closed anticancer drug infusion systems; blood glucose monitoring systems, digital blood pressure monitors, digital thermometers, pulse oximeters, walking intensity monitors, body composition monitors, and HR joint meter/monitors; sprayable adhesion barrier gels; analgesics; pharmaceuticals and nutritional supplements; and peritoneal dialysis devices and fluids. Further, it provides other consumer healthcare products, such as basal thermometers, fall prevention products, oral care products, and urine test strips; and blood bag systems with leukocyte reduction filters, automated blood collection and blood component processing systems, pathogen reduction technology systems, centrifugal apheresis systems, cell expansion systems, and autologous cell processing devices. The company has a strategic partnership with the Orchestra BioMed, Inc. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

Details
Name: Terumo Corporation
TUO
Exchange: DB
Founded: 1921
¥19,365,411,993
743,124,438
Website: http://www.terumo.co.jp
Address: Terumo Corporation
2-44-1, Hatagaya,
Shibuya-ku,
Tokyo,
151-0072,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4543 Common Stock The Tokyo Stock Exchange JP JPY 06. Jan 1992
OTCPK TRUM.F Common Stock Pink Sheets LLC US USD 06. Jan 1992
DB TUO Common Stock Deutsche Boerse AG DE EUR 06. Jan 1992
OTCPK TRUM.Y ADR Pink Sheets LLC US USD 13. Oct 2008
Number of employees
Current staff
Staff numbers
25,378
Terumo employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 21:05
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/12
Last earnings filing: 2019/06/24
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.